# Soleus Capital

> Soleus Capital is a VC fund backing Health Care and Biotechnology. See 88 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Greenwich, United States
- Total investments: 88
- Last investment: Jul 2026
- Lead investor: 17%
- Fund size: $137M
- Last fund: Feb 2021
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/soleus-capital-management-l-p/
- Website: http://www.soleuscapital.com/

Soleus Capital is a private equity firm.

## Contacts

5 contacts available for Soleus Capital. Shizune tracks 2 team members at Soleus Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/soleus-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 50 | 57% |
| Biotechnology | 47 | 53% |
| Therapeutics | 22 | 25% |
| Medical | 19 | 22% |
| Pharmaceutical | 19 | 22% |

30 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 28 | 32% |
| Series B | 16 | 18% |
| Series C | 14 | 16% |
| Series D | 10 | 11% |
| Venture - Series Unknown | 4 | 5% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 51 | 58% |
| United Kingdom | 5 | 6% |
| Canada | 3 | 3% |
| Denmark | 2 | 2% |
| China | 1 | 1% |

10 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Canner | Partner | 6 | https://shizune.co/investors/profile/david-canner |
| Guy Levy | Founder and Managing Member | 8 | https://shizune.co/investors/profile/guy-levy-2856 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Processa Pharmaceuticals | Processa Pharmaceuticals operates as a pharmaceutical company. The company focuses on development of drug products that are intended to improve the survival and quality of life for patients who have unmet medical need. | $200M | Post-IPO Equity | Jul 29, 2026 |  |
| Crystalys Therapeutics | Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout. | $130M | Series B | Jul 22, 2026 |  |
| Prelude Therapeutics | Prelude Therapeutics is a developer of novel therapies intended to target key drivers of cancer cell growth, survival, and resistance. The company's offerings include developing a pipeline of novel, orally bioavailable, small-molecule therapies to target critical intervention points in pathways of resistance to overcome treatment failure incancer, enabling healthcare providers to discover potential treatments that offer hope to people with cancer.Prelude Therapeutics was founded in 2016 by Krishna Vaddi and is based in Wilmington, Delaware. | $90M | Post-IPO Equity | Apr 21, 2026 |  |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M | Post-IPO Equity | Apr 16, 2026 |  |
| Aprea | Aprea is a Swedish biotech company focusing on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53. The Company's lead program, APR-246, is a first-in-class small molecule drug candidate in clinical development. Aprea's main shareholder is KDev Investments AB, an investment vehicleowned by Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital Ltd. Other shareholders include Östersjöstiftelsen, Praktikerinvest, and KCIF Co-Investment Fund KB. | $30M | Post-IPO Equity | Mar 30, 2026 |  |
| Heidelberg Pharma Research | Heidelberg Pharma GmbH, a drug development company, provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. It offers services, such as explorative pharmacology, drug metabolism and pharmacokinetics analysis, and molecular biology inthe fields of oncology or inflammatory/autoimmune diseases. | $20M | Post-IPO Debt | Mar 07, 2026 |  |
| Candid Therapeutics | Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions. | $505M |  | Mar 02, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| C4 Therapeutics | C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causingproteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash.C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs.The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber. | $125M | Post-IPO Equity | Oct 16, 2025 |  |
| Quoin Pharmaceuticals | Quoin Pharmaceuticals is into developing products which address major unmet medical needs including the opioid epidemic and the military veteran suicide rate and chronic rare skin diseases such as Netherton syndrome and Dystrophic Epidermolysis Bullosa (DEB). | $104.5M | Post-IPO Equity | Oct 10, 2025 |  |

10 of 88 investments shown.

## Co-investors
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 33 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 19 deals together
- [Janus Henderson Investors](https://shizune.co/investors/profile/janus-henderson-investors) — VC Fund, 17 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 13 deals together
- [Farallon Capital Management](https://shizune.co/investors/profile/farallon-capital-management) — VC Fund, 13 deals together
- [RTW Investments](https://shizune.co/investors/profile/rtw-investments-llc) — VC Fund, 12 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Soleus Capital invest in?

Soleus Capital invests primarily in Health Care, Biotechnology and Therapeutics startups, most often at Post-IPO Equity and Series B stage. Most of the 88 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Soleus Capital?

Public channels for Soleus Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Soleus Capital?

The team at Soleus Capital includes David Canner (Partner) and Guy Levy (Founder and Managing Member). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co